

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Panchal, et al.

SERIAL NO

199/022,127

FILED

October 30, 2001

TITLE

HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDES AND

METHODS OF USE FOR SAME

Conf. No.

1718

Docket No.

P03357US2

TRANSMITTAL LETTER

To the Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, pursuant to 37 CFR 1.821(e), applicant respectfully submits the following remarks.

A paper copy of the sequence listing accompanied the above-identified continuation application filed October 30, 2001, along with a request for the transfer of the computer readable copy of the sequences from the parent application, serial number 09/229,212. A copy of the above-mentioned documents are enclosed for the Examiner's review. It is submitted that this complies with the sequence requirements.

It is believed no fees are required at this time. However if any additional fees are needed, please charge Deposit Account No. 26-0084.

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this document and the documents referred to as enclosed therein are being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this _____ day of february, 2002/

Respectfully submitted,

Heldi S. Nebel, Reg. No. 37,719

McKEE, VOORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200 Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667


Fax No. (515) 288-1338 CUSTOMER NO: 22885

Attorneys of Record

- pw -







United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/022,127

10/30/2001

Rekha G. Panchal

P03357US2

22885 MCKEE, VOORHEES & SEASE, P.L.C. 801 GRAND AVENUE SUITE 3200 DES MOINES, IA 50309-2721



CONFIRMATION NO. 1718
FORMALITIES LETTER
OC000000007332741

Date Mailed: 01/18/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARKIOFFICE

APPLICANT

Panchal, et al.

Serial No.:

CONTINUATION APPLICATION OF 09/229,212

Filed:

October 30, 2001

Title:

HUMAN SUPPRESSOR IRNA OLIGONUCLEOTIDES AND J1011 U.S.

METHODS OF USE FOR SAME

Receipt is hereby acknowledged of the accompanying:

• Utility Patent Application Transmittal

Fee Transmittal

Patent Application (54 pages)

Oath/Declaration (previously filed in parent application) 6 pages

Drawings (10 pages)

Application Data Sheet (2 pages)

Statement Under 37 CFR 3.73(b) with copy of recorded assignment

Information Disclosure Statement and PTPO/SB08A and 08B

• Request to Transfer Sequence Listing From Parent Application On October 23, 2001 the above described documents were mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231 HGTRI 1078-154 P03357US2

FEI 25 MILES JUNE PROPERTY OF THE PROPERTY OF



COPY OF PAPERS ORIGINALLY EU ED



ORIGINALLY FILED	
Please type a plus sign (+) inside this box Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no persons are required to response	PTO/SB/05 (11-00) Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number.
UTILITY	Attorney Docket No. P03357US2
PATENT APPLICATION	First Inventor PANCHAL, Rekha G.
TRANSMITTAL	Title HUMAN SUPPRESSOR tRNA OLIGONUCLEOTIDE
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label No. EL911005635US
APPLICATION ELEMENTS	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Workington DO 20034
See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. Specification [Total Pages 54] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4.	Washington, DC 20231 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Naceotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. Assignment Papers (cover sheet & document(s)) 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35
6. Application Data Sheet. See 37 CFR 1.76	or its equivalent. 17. Other:
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: V Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09 , 229,212 Prior application Information: Examiner J. Epps Group Art Unit: 1635 For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	
Customer Number or Bar Code Label	or Correspondence address below
Name	
Address	
City	State Zip Code
Country Tele	phone 515-288-3667 Fax 515-288-1338
Name (Print/Type) Fleidi S/Nebel Registration No. (Attorney/Agent) 37,719	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete Time will vary sepending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.